After some brief remarks on the pathogenesis of vasomotor cephalea, the properties of the antiaminic drug BC 105 (Sandomigran) are described and the results reported of using it in 171 patients suffering from cephalea of three types: vasomotor cephalea in 50 cases, vasomotor cephalea with associated neurosic component in 26 cases, and post-traumatic cephalea in 95 cases. In the first two types, the positive results obtained confirm the usefulness of BC 105 in basic treatment of vasomotor cephalea. In post-traumatic cephalea which is a notoriously difficult therapeutic problem, the results obtained, although only partially positive, are worthy of the fullest consideration.